World Cancer Day: Genomics & AI Blood Test Detects Cancer Before Symptoms Appear in India
Publisher:Gene Solutions
Publication date:05 February 2026
Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.
Key finding:
IRVINE, Calif., Jan. 21, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests (LDTs), announced a strategic collaboration to advance U.S. verification and clinical validation of liquid biopsy assays designed for cancer detection, profiling, and monitoring.Authors:
Gene Solutions Genomics Pte LtdPublisher:PR Newswire
Publication date:21 January 2026
Gene Solutions Concludes Successful ESMO Asia Congress 2025 with AI-Powered Multi-Omics Liquid Biopsy Symposium and Two Best Poster Awards
Key finding:
SINGAPORE, Dec. 20, 2025 /PRNewswire/ — Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medical Oncology (ESMO) Asia Congress 2025—held in Singapore on December 5–7. Highlights included a full-house symposium, seven scientific abstracts with two earning Best Poster designations, and meaningful engagement with thousands of oncologists from across the Asia-Pacific region at the company’s exhibition booth.Authors:
Gene Solutions Genomics Pte LtdPublisher:PR Newswire
Publication date:20 December 2025
Tumor-naïve multimodal profiling of circulating tumor DNA to detect minimal residual disease in solid tumors
Key finding:
The tumor-naïve method could be a reliable alternative to monitor ctDNA when obtaining high-quality tissue samples is challenging. The performance of this method was better in high ctDNA-shedding cancer or at the metastatic stage.Authors:
Tu Nguyen, Van-Anh Nguyen Hoang, Trong Hieu Nguyen, Trung Hieu Tran, Ngoc Nguyen, Tho Thi Le Vo, Duy Sinh Nguyen, Hoa Giang, Hoai-Nghia Nguyen, and Lan N. TuPublisher:Therapeutic Advances in Medical Oncology
Publication date:18 November 2025This publication supports for the following genetic testing:
Tumor Genomic and Transcriptomic Analysis Integrated With Liquid Biopsy ctDNA Monitoring: Analytical Validation and Clinical Insights
Key finding:
Comprehensive genomic profiling (CGP) is a time- and tissue- efficient method to help guide precision oncology. To enhance the clinical utility of CGP, we investigated the performance of a novel strategy integrating tumor DNA and mRNA profiling, together with liquid biopsy ctDNA monitoring. Comprehensive genomic and transcriptomic profiling could reliably unveil genetic details not provided by DNA-only CGP. The integration of ctDNA detection further helped detect tumor-agnostic mutations and monitor treatment response.Authors:
Nam H. B. Tran, Thien-Phuc Hoang Nguyen, Vinh Quang Bui, Vu Thuong Le, Trong Khoa Mai, Van-Anh Nguyen Hoang, Tien Anh Nguyen, Minh-Duc Nguyen, Ha-Hieu Pham, Tho Thi Le Vo, My T. T. Ngo, Du Quyen Nguyen, Duy Sinh Nguyen, Hoai-Nghia Nguyen, Minh-Duy Phan, Hoa Giang, Lan N. TuPublisher:Cancer Medicine
Publication date:08 December 2025This publication supports for the following genetic testing:
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Key finding:
TAIPEI, Nov. 28, 2025 /PRNewswire/ — Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement with the introduction of SPOT-MAS – an advanced screening solution developed by Gene Solutions, a global leader in precision oncology and genomics, in collaboration with local partner Gene Health.Authors:
Gene Solutions Genomics Pte LtdPublisher:PR Newswire
Publication date:28 November 2025
AI and Multi-omics are Transforming Cancer Care: APAC Precision Oncology Conference Outlines the Future of Early Detection and Personalized Treatment
Key finding:
HONG KONG, Nov. 17, 2025 /PRNewswire/ — The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in Cancer Management, convened in Hong Kong on November 1, marking Lung Cancer Awareness Month with a clear message: AI and multi-omics are no longer theoretical – they are driving real-world advancements in cancer care across the Asia-Pacific (APAC) region.Authors:
Gene Solutions Genomics Pte LtdPublisher:PR Newswire
Publication date:01 November 2025
Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials
Key finding:
Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant milestone in advancing precision medicine in Southeast Asia.Authors:
Gene Solutions Genomics Pte LtdPublisher:PR Newswire
Publication date:27 October 2025
Gene Solutions Brings Insights on Advances in MRD and Multi-Omics Technologies to the Singapore Society of Oncology Annual Scientific Meeting 2025
Key finding:
At the Singapore Society of Oncology Annual Scientific Meeting 2025 (SSO ASM 2025), Gene Solutions showcased how Molecular Residual Disease (MRD) and AI-powered multi-omics technologies are advancing precision oncology across Asia-Pacific, reinforcing Singapore’s role as a hub for innovation and global collaboration.Authors:
Gene Solutions Genomics Pte LtdPublisher:PR Newswire
Publication date:16 October 2025
Gene Solutions and AMPATH Launch Advanced Genomics Laboratory in Hyderabad to Expand Access to Precision Medicine in India
Authors:
Gene Solutions Genomics Pte LtdPublisher:PR Newswire
Publication date:01 October 2025
Multimodal analysis of cell-free DNA enhances differentiation of early-stage breast cancer from benign lesions and healthy individuals
Publisher:BMC Biology
Publication date:20 August 2025This publication supports for the following genetic testing:
Combination of BRCA deep targeted sequencing and shallow whole genome sequencing to detect homologous recombination deficiency in ovarian cancer
Key finding:
We developed an assay to accurately determine the homologous recombination deficiency status of ovarian tissue samples, including those with low DNA quality. This study was the first to analyze the prevalence and spectrum of homologous recombination deficiency in Vietnamese patients with ovarian cancer. Comprehensive assessment of homologous recombination deficiency should be performed instead of BRCA1/2 testing alone so that no patients miss their opportunity for PARPi treatment.Authors:
Thien-Phuc Nguyen Hoang , Nam H. B. Tran , Tien Anh Nguyen, My T. T. Ngo, Anh Duong Doan, Du Quyen Nguyen, Hung Sang Tang, Duy Sinh Nguyen, Cam Tu Nguyen Thi, Thanh Thuy Do Thi , Hoai-Nghia Nguyen, Hoa Giang and Lan N. TuPublisher:Frontier
Publication date:01 September 2025This publication supports for the following genetic testing:
1
2
3
4
5
…
8
